ARAV - Aravive sinks as Phase 3 ovarian cancer trial for lead asset fails
2023-08-03 08:52:55 ET
More on Aravive
- Aravive: Very Small Company With Late Stage Trial In Ovarian Cancer
- Aravive stock pops on FDA orphan drug status for batiraxcept to treat pancreatic cancer
- Aravive gains on FDA Fast Track status for lead program
- Aravive to raise $41.5M in direct stock offering
- Seeking Alpha’s Quant Rating on Aravive
For further details see:
Aravive sinks as Phase 3 ovarian cancer trial for lead asset fails